Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 4, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 9, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001644888-26-000009
Filed / recorded
Oct 9, 2026, 12:00 AM UTC
Added to OQRO
Oct 9, 2026, 1:25 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Attovia Therapeutics, Inc.
Issuer CIK
2058707
Ticker
ATTO
Reporting person
Tao Fu
Relationship
Director, Officer
Officer title
President and CEO
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Aug 4, 2026
Transaction code
A
Shares / units
538,300
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
538,300
Ownership form
Direct
Amendment
Yes (Form 4/A)
Footnotes from the filing
25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.